Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Neuropsychopharmacology

• Publication date

  2016-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.euroneuro.2017.05.005PMID 28576350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The changes of the cognitive and psychomotor functions in the chronic cannabis users after a month of remission

  2016cited by this paper
• “I Use Weed for My ADHD”: A Qualitative Analysis of Online Forum Discussions on Cannabis Use and ADHD

  2016cited by this paper
• Adult attention-deficit hyperactivity disorder: key conceptual issues.

  2016cited by this paper
• Attention-deficit/hyperactivity disorder

  2015cited by this paper
• Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum

  2015cited by this paper
• Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

  2015cited by this paper
• Reliablity anf Validity of Weiss Functional Impairment Rating Scale (WFIRS)-Thai version in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

  2015cited by this paper
• Objective QbTest and subjective evaluation of stimulant treatment in adult attention deficit-hyperactivity disorder

  2015influential reference
• Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

  2014cited by this paper
• Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis.

  2014cited by this paper
• Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.

  2014cited by this paper
• Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology

  2014cited by this paper
• Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.

  2014cited by this paper
• Subtypes of Attention Deficit-Hyperactivity Disorder (ADHD) and Cannabis Use

  2014cited by this paper
• Considering Cannabis: The Effects of Regular Cannabis Use on Neurocognition in Adolescents and Young Adults

  2014cited by this paper
• Impact of ADHD and cannabis use on executive functioning in young adults.

  2013cited by this paper
• Affective Lability Scales

  2013cited by this paper
• Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

  2013cited by this paper
• An epidemiological study of ADHD symptoms among young persons and the relationship with cigarette smoking, alcohol consumption and illicit drug use.

  2012cited by this paper
• Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units

  2012cited by this paper
• Neural and behavioral endophenotypes in ADHD.

  2012cited by this paper
• Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

  2012cited by this paper
• Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology

  2012cited by this paper
• ADHD and offenders

  2011cited by this paper
• Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.

  2011cited by this paper
• A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use

  2011cited by this paper
• Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study

  2011cited by this paper
• An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive Functions

  2011cited by this paper
• Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being

  2011cited by this paper
• Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study

  2010cited by this paper
• Heinrich Begehr: Citation for his 70th birthday

  2010cited by this paper
• Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge

  2010cited by this paper
• Diagnostic Interview for ADHD in adults (DIVA)

  2010cited by this paper
• Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum

  2009cited by this paper
• Two Types of Action Error: Electrophysiological Evidence for Separable Inhibitory and Sustained Attention Neural Mechanisms Producing Error on Go/No-go Tasks

  2009cited by this paper
• ALTERED ANANDAMIDE DEGRADATION IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

  2009cited by this paper
• Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis

  2009cited by this paper
• Can recreational doses of THC produce significant dopamine release in the human striatum?

  2009influential reference
• Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users

  2009cited by this paper
• Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis

  2008cited by this paper
• Cannabis improves symptoms of ADHD

  2008cited by this paper
• Potency of Δ9–THC and Other Cannabinoids in Cannabis in England in 2005: Implications for Psychoactivity and Pharmacology *

  2008cited by this paper
• Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum

  2008cited by this paper
• Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

  2008cited by this paper
• Developing and evaluating complex interventions: the new Medical Research Council guidance

  2008cited by this paper
• The chronic effects of cannabis on memory in humans: a review.

  2008cited by this paper
• The worldwide prevalence of ADHD: a systematic review and metaregression analysis.

  2007cited by this paper
• Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double‐blind, placebo‐controlled clinical trial

  2007cited by this paper
• Mixed Amphetamine Salts Extended-Release in the Treatment of Adult ADHD: A Randomized, Controlled Trial

  2006cited by this paper
• Fonte: Dica 33 - FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides

  2006cited by this paper
• High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control

  2006cited by this paper
• Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

  2006cited by this paper
• Effects of atomoxetine and methylphenidate on sleep in children with ADHD.

  2006cited by this paper
• Evidence-Based Guidelines?

  2005cited by this paper
• Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects

  2004influential reference
• The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials.

  2004cited by this paper
• The affective lability scales: Development of a short-form measure

  2004cited by this paper
• Being stoned: a review of self-reported cannabis effects.

  2003cited by this paper
• Effects of THC on Behavioral Measures of Impulsivity in Humans

  2003cited by this paper
• Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

  2003cited by this paper
• An Evidence-Based Review

  2002cited by this paper
• Cannabis induced dopamine release: an in-vivo SPECT study.

  2001cited by this paper
• Prevalence and implications of attention-deficit hyperactivity disorder among adolescents in treatment for substance abuse.

  1997cited by this paper
• A self report measure of affective lability

  1997cited by this paper
• Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity.

  1995cited by this paper
• Attention-deficit hyperactivity disorder in adults.

  1995influential reference
• Psychoactive Substance Use Disorders

  1994cited by this paper
• Intention to treat--who should use ITT?

  1993cited by this paper
• Attention-De fi cit / Hyperactivity Disorder and Substance Abuse

  year unknowncited by this paper

• Mapping ADHD Heterogeneity and Biotypes by Topological Deviations in Morphometric Similarity Networks.

  2026cites this paper
• Connecting the dots and finding the way forward: Pharmacological, neuromodulatory, and psychotherapeutic interventions for the complex treatment of adult ADHD.

  2026cites this paper
• Distinct serum endocannabinoid profiles in treatment-naïve Han Chinese children with ADHD: a case–control pilot study

  2026cites this paper
• A Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health

  2025cites this paper
• Cannabis and Cannabinoids: A Primer

  2025cites this paper
• Case Report: Effect of medicinal cannabis on fitness to drive in a patient with Tourette Syndrome and ADHD

  2025cites this paper
• Efectos terapéuticos de los componentes del cannabis

  2025cites this paper
• Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder

  2025cites this paper
• New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder

  2025cites this paper
• Mapping ADHD Heterogeneity and Biotypes through Topological Deviations in Morphometric Similarity Networks

  2025cites this paper
• The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis

  2025cites this paper
• Canabidiol como intervenção farmacológica no transtorno de déficit de atenção e hiperatividade (TDAH): uma revisão narrativa

  2025cites this paper
• Biochemical Role of the Endocannabinoid System in the Pathophysiology of Attention Deficit Hyperactivity Disorder: A Narrative Review and Future Directions

  2025cites this paper
• Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review

  2025cites this paper
• New treatments for OCD? Evidence for cannabinoids and psychedelics.

  2025cites this paper
• Verordnung von Cannabinoiden

  2025cites this paper
• Cannabinoids and ADHD: a New Frontier in Neuropharmacology?

  2025influential citation
• Retrospective Observations from a Pilot Study on the Feasibility and Safety of Medication Reduction or Withdrawal in Children with Autism Spectrum Disorder Taking Cannabidiol-Rich Oil

  2025cites this paper
• A naturalistic examination of the effects of chronic and acute cannabis use on cognition and perceived symptoms of attention-deficit/hyperactivity disorder.

  2025cites this paper
• The differential effects of medicinal cannabis on mental health: A systematic review.

  2025cites this paper
• Medical cannabis for children: Evidence and recommendations.

  2024cites this paper
• The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray.

  2024cites this paper
• OS BENEFÍCIOS DO CANABIDIOL NO TRATAMENTO EM CRIANÇAS COM TRANSTORNOS NEURODIVERGENTES

  2024cites this paper
• IMPACTOS DO USO DE CANNABIS EM INDIVÍDUOS COM TDAH: EFEITOS COGNITIVOS, DECISÕES E POSSÍVEIS BENEFÍCIOS TERAPÊUTICOS

  2024cites this paper
• Medicinal Cannabinoids in Controlling ADHD Symptoms Among Children and Adolescents: What is the Evidence?

  2024influential citation
• Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA

  2024cites this paper
• Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder

  2024cites this paper
• Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults.

  2024cites this paper
• Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial

  2024cites this paper
• Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer’s Disease

  2024cites this paper
• The Use of Compounds Derived from Cannabis sativa in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders

  2024cites this paper
• Les données probantes et les recommandations sur le cannabis à des fins médicales chez les enfants.

  2024cites this paper
• Pharmacologic and Non-Pharmacologic Interventions for Emotional Lability: A Meta-Analysis.

  2023cites this paper
• Cannabis – A state of the art about the millenary plant: Part I

  2023cites this paper
• CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.

  2023cites this paper
• [Attention deficit hyperactivity disorder and substance use in adulthood-Guideline-conform diagnostics and treatment].

  2023cites this paper
• Aufmerksamkeitsdefizit‑/Hyperaktivitätsstörung und Substanzkonsum im Erwachsenenalter – leitliniengerechte Diagnostik und Behandlung

  2023cites this paper
• The study of rs324420 (C385A) polymorphism of the FAAH gene of the endocannabinoid system in patients with epilepsy and ADHD.

  2023cites this paper
• Prescribing Stimulants for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Co-Occurring Cannabis Use: Considerations for Managing a Clinical Dilemma.

  2023cites this paper
• Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression

  2023cites this paper
• Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing

  2023cites this paper
• Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review

  2023cites this paper
• Medizinisches Cannabis

  2023cites this paper
• Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders

  2023cites this paper
• Exploring the Link Between Attention-Deficit Hyperactivity Disorder and Cannabis Use Disorders: A Review

  2023cites this paper
• A Scoping Review of Factors Associated With Emotional Dysregulation in Adults With ADHD

  2023cites this paper
• Medical cannabis and attention-deficit hyperactivity disorder

  2023cites this paper
• The long-term neurodevelopmental outcomes of febrile seizures and underlying mechanisms

  2023cites this paper
• Cannabisarzneimittel in der Behandlung psychischer Störungen – Befunde aus der Cannabis-Begleiterhebung des Bundesinstituts für Arzneimittel und Medizinprodukte

  2023cites this paper
• Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature

  2023cites this paper
• UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention‐deficit/hyperactivity disorder

  2023cites this paper
• The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review

  2023cites this paper
• Potential Medical Benefits of Cannabis sativa and Its Controversies

  2023cites this paper
• Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia.

  2023cites this paper
• FAAH rs324420 Polymorphism: Biological Pathways, Impact on Elite Athletic Performance and Insights for Sport Medicine

  2023cites this paper
• O PAPEL DA CANNABIS MEDICINAL PARA O TRATAMENTO DO TRANSTORNO DO DÉFICIT DE ATENÇÃO COM HIPERATIVIDADE (TDAH): REVISÃO INTEGRATIVA DE LITERATURA

  2023cites this paper
• Cannabis-based medicinal products (CBMPs) for the treatment of Long COVID symptoms: current and potential applications

  2023cites this paper
• Parental Perceptions and Usage of Unlicensed Cannabidiol Products in Children With Anxiety and Neurodevelopmental Disorders.

  2023cites this paper
• A systematic review of cannabidiol trials in neurodevelopmental disorders.

  2023cites this paper
• Cannabis use in Attention - Deficit/Hyperactivity Disorder (ADHD): A scoping review.

  2022cites this paper
• The effect of medical cannabis on cognitive functions: a systematic review

  2022cites this paper
• The role of cannabinoids in neurodevelopmental disorders of children and adolescents

  2022cites this paper
• Interventions for ADHD in children & adolescents with epilepsy: A review and decision tree to guide clinicians.

  2022cites this paper
• The use of cannabinoids in the treatment of attention deficit hyperactivity disorder - a review of the latest literature.

  2022cites this paper
• Autism and associated disorders: cannabis as a potential therapy.

  2022cites this paper
• Cannabis for the Treatment of Attention Deficit Hyperactivity Disorder: A Report of 3 Cases

  2022cites this paper
• Predicting Self-Medication with Cannabis in Young Adults with Hazardous Cannabis Use

  2022cites this paper
• Attention deficit hyperactivity disorder symptoms and cannabis use after 1 year among students of the i-Share cohort

  2022cites this paper
• Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders

  2022influential citation
• University students with attention deficit hyperactivity disorder (ADHD): a consensus statement from the UK Adult ADHD Network (UKAAN)

  2022cites this paper
• Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models

  2022cites this paper
• Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders

  2022cites this paper
• Cannabisgebrauch bei Jugendlichen

  2022cites this paper
• Attention-Deficit Hyperactivity Disorder and Therapeutic Cannabis Use Motives.

  2022cites this paper
• Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  2022cites this paper
• Self-Reported Effects of Cannabis on ADHD Symptoms, ADHD Medication Side Effects, and ADHD-Related Executive Dysfunction

  2021cites this paper
• Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review.

  2021cites this paper
• Cannabis Legalization and College Mental Health

  2021cites this paper
• Targeting the Endocannabinoid System in the Treatment of ADHD

  2021cites this paper
• Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics.

  2021cites this paper
• Naturalistic exploratory study of the associations of substance use on ADHD outcomes and function

  2021cites this paper
• Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention

  2021cites this paper
• Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study

  2021cites this paper
• Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials.

  2021cites this paper
• Treatments with cannabinoids and brain development

  2021cites this paper
• Evaluación del Consumo de Drogas en Adolescentes con y sin TDAH. Nuevas Evidencias y Recomendaciones

  2021cites this paper
• Sphingolipid and Endocannabinoid Profiles in Adult Attention Deficit Hyperactivity Disorder

  2021cites this paper
• Wonder or evil?: Multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals

  2021cites this paper
• Cannabinoid Drugs in Mental Health Disorders

  2021cites this paper
• Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study

  2021cites this paper
• Autism Spectrum Disorder

  2021cites this paper
• Endocannabinoid System

  2021cites this paper
• Cannabinoids, the Endocannabinoid System, and Cognitive Functions: Enemies or Friends?

  2021cites this paper
• The use of psychoactive substances in the treatment of mental disorders

  2021cites this paper
• Cannabis and cannabidiol use among autistic and non-autistic adults in the UK: a propensity score-matched analysis

  2021cites this paper
• Cannabis for psychiatric disorders - Has The Pendulum Swung Too Far?

  2021cites this paper
• Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies

  2020cites this paper
• Clinical Documentation for QbTest and QbCheck

  2020cites this paper
• Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story.

  2020cites this paper
• The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders


  2020cites this paper